Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Sci Rep ; 11(1): 9615, 2021 05 05.
Article in English | MEDLINE | ID: mdl-33953230

ABSTRACT

We explore the possibility that chemical feedback and autocatalysis in oscillating chemical reactions could amplify weak magnetic field effects on the rate constant of one of the constituent reactions, assumed to proceed via a radical pair mechanism. Using the Brusselator model oscillator, we find that the amplitude of limit cycle oscillations in the concentrations of reaction intermediates can be extraordinarily sensitive to minute changes in the rate constant of the initiation step. The relevance of such amplification to biological effects of 50/60 Hz electromagnetic fields is discussed.

2.
Clin Transl Allergy ; 10: 10, 2020.
Article in English | MEDLINE | ID: mdl-32337019

ABSTRACT

BACKGROUND: Pollen and house dust mite (HDM) subcutaneous immunotherapy (SLIT) and pollen subcutaneous immunotherapy (SCIT) are effective therapies for children with allergic rhinoconjunctivitis (AR). There are no previous direct comparative studies investigating quality of life (QoL) of all three immunotherapy regimes. The aim of this study was to compare QoL and safety in children receiving these immunotherapies for AR. METHODS: Demographic characteristics, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Visual Analogue (VAS) scores were assessed in 249 children undergoing HDM and pollen immunotherapy at a UK specialist paediatric centre between 2007 and 2019. RESULTS: All three immunotherapy regimes led to a > 50% improvement in QoL and VAS after 3 years of therapy, with significant improvements by the end of the first year (p < 0.05) and further improvements between 1 and 3 years (p < 0.05). Age, gender, ethnicity and route of administration had no significant bearing on efficacy. Older, polysensitised children and those receiving HDM SLIT were all more likely to discontinue their treatment (all with p < 0.05). The only patient to suffer from anaphylaxis requiring intramuscular adrenaline, and 80% experiencing exacerbations of their asthma had received pollen SCIT. CONCLUSIONS: Pollen SCIT and pollen and HDM SLIT all lead to significant improvements in QoL. The risk of anaphylaxis is low, but SCIT is associates with a 1 in 5 chance of asthma flares in the days after its administration. Discontinuation of therapy is more frequent in older, polysensitised children, and those undergoing HDM immunotherapy.

SELECTION OF CITATIONS
SEARCH DETAIL